Literature DB >> 31038154

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.

S B van Waalwijk van Doorn-Khosrovani1, A Pisters-van Roy1, L van Saase2, M van der Graaff2, J Gijzen1, S Sleijfer3, L R Hoes4, J M van Berge Henegouwen5, H van der Wijngaart6, D L van der Velden4, E van Werkhoven7, V P Retel8, W H van Harten9, A D R Huitema10, L Timmers2, H Gelderblom5, H M W Verheul5, E E Voest11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31038154     DOI： 10.1093/annonc/mdz119

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.

Authors:  Jorn Mulder; Odile C van Stuijvenberg; Paula B van Hennik; Emile E Voest; Anna M G Pasmooij; Violeta Stoyanova-Beninska; Anthonius de Boer
Journal:  Front Med (Lausanne)       Date:  2022-06-14

Review 2.  Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards.

Authors:  Edoardo Crimini; Matteo Repetto; Paolo Tarantino; Liliana Ascione; Gabriele Antonarelli; Elena Guerini Rocco; Massimo Barberis; Luca Mazzarella; Giuseppe Curigliano
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

3.  Learning health care systems: Highly needed but challenging.

Authors:  Roel H P Wouters; Rieke van der Graaf; Emile E Voest; Annelien L Bredenoord
Journal:  Learn Health Syst       Date:  2020-01-13

4.  Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Authors:  Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas
Journal:  Appl Health Econ Health Policy       Date:  2022-04-04       Impact factor: 3.686

5.  Manufacturers' views on outcome-based agreements.

Authors:  Sahar Barjestehvan Waalwijk van Doorn-Khosrovani; Lonneke Timmers; Anke Pisters-van Roy; Joël Gijzen; Nicole M A Blijlevens; Haiko Bloemendal
Journal:  J Mark Access Health Policy       Date:  2021-10-29

6.  Outcome-based reimbursement in Central-Eastern Europe and Middle-East.

Authors:  Ildikó Ádám; Marcelien Callenbach; Bertalan Németh; Rick A Vreman; Cecilia Tollin; Johan Pontén; Dalia Dawoud; Jamie Elvidge; Nick Crabb; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Anke Pisters-van Roy; Áron Vincziczki; Emad Almomani; Maja Vajagic; Z Gulsen Oner; Mirna Matni; Jurij Fürst; Rabia Kahveci; Wim G Goettsch; Zoltán Kaló
Journal:  Front Med (Lausanne)       Date:  2022-09-23

7.  Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.

Authors:  Jorn Mulder; Robin Verjans; Ciska Verbaanderd; Elias Pean; Just Weemers; Hubert G M Leufkens; Francesco Pignatti; Anthonius de Boer; Emile E Voest; Violeta V Stoyanova-Beninska; Anna M G Pasmooij
Journal:  Front Med (Lausanne)       Date:  2021-12-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.